PRLR and neoplasm: In a patient-derived xenograft (PDX) study with CTG-0869 (0.8x the total PRLR as in the MCF7 cell line), ABBV-176 also exhibited potent anti-tumor activity when compared to vehicle and non-targeted control PBD ADC at the highest dose, 0.5 mg/kg, as well as the 0.3 mg/kg, 0.2 mg/kg, and 0.1 mg/kg doses administered Q7D × 3, which induced durable tumor regression, with similar results seen for CTG-0670 (Fig. 2B and C, (p < 0.05), and Table 2).